Erysipelas laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 19: Line 19:
**The [[Lancefield]] [[antigen]] test will determine the specific [[antibodies]] produced by the β-[[hemolytic]] [[streptococcal]] infection, allowing classification into group A, B, C, or G ''[[streptococcus]]''.
**The [[Lancefield]] [[antigen]] test will determine the specific [[antibodies]] produced by the β-[[hemolytic]] [[streptococcal]] infection, allowing classification into group A, B, C, or G ''[[streptococcus]]''.
**The Pyrrolidonyl Arylamidase (PYR) test is used to determine if the infection is ''[[Streptococcus pyogenes]]'' by testing for confirmed presence of pyrrolidonyl [[aminopeptidase]]
**The Pyrrolidonyl Arylamidase (PYR) test is used to determine if the infection is ''[[Streptococcus pyogenes]]'' by testing for confirmed presence of pyrrolidonyl [[aminopeptidase]]
**
**[[Bacitracin]] susceptibility testing is used as a next subsequent measure of specifying the [[streptococcal]] strain when PYR test results are positive, separating ''[[Streptococcal pyogenes]]'' from other β-[[hemolytic]] strains.
 
***Results of [[bacitracin]] sensitivity indicate positive ''[[Streptococcal pyogenes]]'' test results.<ref name="urlwww.cdc.gov">{{cite web |url=https://www.cdc.gov/streplab/downloads/general-methods-sections1-2.pdf |title=www.cdc.gov |format= |work= |accessdate=}}</ref>


==References==
==References==

Revision as of 15:57, 14 September 2016

Erysipelas Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Erysipelas from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Erysipelas laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Erysipelas laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Erysipelas laboratory findings

CDC on Erysipelas laboratory findings

Erysipelas laboratory findings in the news

Blogs on Erysipelas laboratory findings

Directions to Hospitals Treating Erysipelas

Risk calculators and risk factors for Erysipelas laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.

Overview

Laboratory Findings

Laboratory tests and findings for Erysipelas include those used to confirm streptococcal infection for pathogenic strains.

Culture

Streptococcal Identification Tests

References

  1. Ferretti JJ, Stevens DL, Fischetti VA, Stevens DL, Bryant AE. PMID 26866211. Missing or empty |title= (help)
  2. "www.cdc.gov" (PDF).

Template:WH Template:WS